However, large differences in HER-low rates in different studies (from 10% up to 100%) as well as dynamics of HER2 expression during treatment indicate that HER2 levels can serve as a marker for different biological processes in the tumor, even in TNBC, rather than as a biological driver of these processes. The gene discussed is ERBB2; the disease is neoplasm.